Abstract
Human genetic studies of smoking behavior have been so far largely limited to common variations. Studying rare coding variants has potential to identify new drug targets and refine our understanding of the mechanisms of known targets. We performed an exome-wide association study (ExWAS) of smoking phenotypes in up to 749,459 individuals across multiple ancestries and discovered a protective association signal in CHRNB2 that encodes the β2 subunit of α4β2 nicotine acetylcholine receptor (nAChR). Rare predicted loss-of-function (pLOF) and likely deleterious missense variants in CHRNB2 in aggregate were associated with a 35% decreased odds for smoking more than 10 cigarettes per day (OR=0.65, CI=0.56-0.76, P=1.9e-8). An independent common variant association in the protective direction (rs2072659; OR=0.96; CI=0.94-0.98; P=5.3e-6) was also evident, suggesting an allelic series. The protective effects of both rare and common variants were detectable to some extent on phenotypes downstream of smoking including lung function, emphysema, chronic obstructive pulmonary disease (COPD) and lung cancer. α4β2 is the predominant nAChR in human brain and is one of the targets of varenicline, a partial nAChR agonist/antagonist used to aid smoking cessation. Our findings in humans align with decades-old experimental observations in mice that β2 loss abolishes nicotine mediated neuronal responses and attenuates nicotine self-administration. Our genetic discovery will inspire future drug designs targeting CHRNB2 in the brain for the treatment of nicotine addiction.
Competing Interest Statement
The authors declare the following competing interests: Regeneron authors receive salary from and own options and/or stock of the company. The remaining authors declare no competing interests.
Funding Statement
We thank the UK Biobank team, their funders, the dedicated professionals from the member institutions who contributed to and supported this work, and the UK Biobank participants. The exome sequencing was funded by the UK Biobank Exome Sequencing Consortium (i.e., Bristol Myers Squibb, Regeneron, Biogen, Takeda, AbbVie, Alnylam, AstraZeneca and Pfizer). This research has been conducted using the UK Biobank Resource under application number 2604. We thank the MyCode Community Health Initiative participants for taking part in the DiscovEHR collaboration. This research received funding from Regeneron Pharmaceuticals. We thank the participants of the MCPS cohort. The MCPS has received funding from the Mexican Health Ministry, the National Council of Science and Technology for Mexico, the Wellcome Trust, Cancer Research UK, British Heart Foundation and the UK Medical Research Council. These funding sources had no role in the design, conduct or analysis of the study or the decision to submit the manuscript for publication. Genotyping, exome sequencing and whole genome sequencing was funded through an academic partnership between the National Autonomous University of Mexico, the University of Oxford, Regeneron, AstraZeneca and Abbvie. The computational aspects of this research were supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the UK Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the study participants have provided informed consent and all the participating cohorts have received ethical approval from their respective institutional review board (IRB). The UK Biobank project has received ethical approval from the Northwest Centre for Research Ethics Committee (11/NW/0382). The work described here has been approved by the UKB (application no. 26041). The GHS project has received ethical approval from the Geisinger Health System Institutional Review Board under project no. 2006-0258. The MCPS study has received ethical approval from the Mexican Ministry of Health, the Mexican National Council for Science and Technology, and the University of Oxford. The BioMe biobank has received ethical approval from the IRB at the Icahn School of Medicine at Mount Sinai.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UKB individual-level genotypic and phenotypic data are available to approved investigators via the UK Biobank study (www.ukbiobank.ac.uk/). Additional information about registration for access to the data are available at www.ukbiobank.ac.uk/register-apply/. Data access for approved applications requires a data transfer agreement between the researcher's institution and UK Biobank, the terms of which are available on the UK Biobank website (www.ukbiobank.ac.uk/media/ezrderzw/applicant-mta.pdf). GHS individual-level data are available to qualified academic noncommercial researchers through the portal at https://regeneron.envisionpharma.com/vt_regeneron/ under a data access agreement. The MCPS represents a long-standing collaboration between researchers at the National Autonomous University of Mexico (UNAM) and the University of Oxford. The investigators welcome requests from researchers in Mexico and elsewhere who wish to access MCPS data. If you are interested in obtaining data from the study for research purposes, or in collaborating with MCPS investigators on a specific research proposal, please visit https://www.ctsu.ox.ac.uk/research/prospective-blood-based-study-of-150-000-individuals-in-mexico where you can download the study's Data and Sample Access Policy in English or Spanish. The policy lists the data available for sharing with researchers in Mexico and in other parts of the world. Full details of the data available may also be viewed at https://datashare.ndph.ox.ac.uk/.
